Imagine a world where a painful and sometimes deadly virus could be stopped in its tracks by a simple, cost-effective solution. That’s exactly what researchers are now closer to achieving with the help of artificial intelligence (AI) in the fight against monkeypox (mpox). But here’s where it gets even more groundbreaking: this innovation could also revolutionize how we tackle smallpox, a virus with terrifying potential as a bioterrorism weapon. An international team of scientists, leveraging AI, has identified a viral surface protein that could be the key to a new vaccine or antibody therapy for mpox—a disease that, in 2022, infected over 150,000 people worldwide and claimed nearly 500 lives. The current smallpox vaccine, repurposed during the mpox outbreak, is complex and expensive, making it less accessible for those who need it most, including children, pregnant women, and immunocompromised individuals.
And this is the part most people miss: the breakthrough lies in a single protein, OPG153, which is far simpler to produce than a whole-virus vaccine. Jason McLellan, a professor of molecular biosciences at The University of Texas at Austin, explains, 'Unlike a whole-virus vaccine that’s big and complicated to produce, our innovation is just a single protein that’s easy to make.' This simplicity could make the vaccine more affordable and scalable, potentially saving countless lives.
The journey to this discovery began with identifying 12 antibodies that effectively neutralize the monkeypox virus (MPXV). Researchers used blood from patients who had either recovered from mpox or been vaccinated against it. However, the challenge was pinpointing which of the dozens of surface proteins on the virus these antibodies targeted. Enter AI—specifically, the AlphaFold 3 model—which predicted with high confidence that certain antibodies would bind to OPG153. Follow-up experiments confirmed this, marking a significant leap forward in vaccine development.
But here’s where it gets controversial: While this approach, dubbed 'reverse vaccinology' by McLellan, shows immense promise, it raises questions about the role of AI in scientific discovery. Could AI replace traditional lab work? Or is it merely a tool that accelerates human ingenuity? McLellan notes, 'It would have taken years to find this target without AI,' highlighting its transformative potential. Yet, some argue that relying too heavily on AI could overshadow the critical thinking and creativity of human researchers. What do you think? Is AI a game-changer or just another tool in the scientific toolbox?
The team is now working to refine the vaccine antigen and antibodies, aiming for greater efficacy and lower production costs. Their ultimate goal? To test these innovations in humans, offering protection not only against mpox but also smallpox. UT Austin has filed a patent for OPG153 as a vaccine antigen, while the Fondazione Biotecnopolo di Siena in Italy has patented the antibodies targeting it. This collaboration underscores the power of global scientific efforts in tackling some of the world’s most pressing health challenges.
Here’s a thought to leave you with: If this AI-driven approach succeeds, could it set a precedent for how we develop vaccines and therapies for other diseases? Let us know your thoughts in the comments—do you see AI as the future of medical research, or are there limits to its role? The conversation starts here.
